Metformin for prevention of cesarean delivery and large-for-gestational-age newborns in non-diabetic obese pregnant women: a randomized clinical trial
Open Access
- 5 June 2020
- journal article
- research article
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 64 (3) , 290-297
Abstract
To evaluate the use of metformin for preventing cesarean deliveries and large-for-gestational-age (LGA) newborn (NB) outcomes in non-diabetic obese pregnant women. This is a randomized clinical trial with obese pregnant women, divided into 2 groups: metformin group and control group, with followed-up prenatal routine. The gestational age of participants was less than or equal to 20 weeks and were monitored throughout entire prenatal period. For outcomes of delivery and LGA newborns, absolute risk reduction (ARR) and the number needed to treat (NNT) were calculated with a 95% confidence interval (CI). 357 pregnant women were evaluated. From the metformin group (n = 171), 68 (39.8%) subjects underwent cesarean delivery, and 117 (62.9%) subjects from the control group (n = 186) had intercurrence (p < 0.01). As for the mothers' general characteristics, there was significance for marital status (p < 0.01). Maternal-fetal results presented reduced preeclampsia (p < 0,01). Primary prophylactic results presented an ARR of 23.1 times (95% CI: 13.0-33.4) with NNT of 4 (95% CI: 3.0-7.7) and no significant values for LGA NB (p > 0.01). Secondary prophylactic outcomes presented decreased odds ratio for preeclampsia (OR = 0.17, 95% CI: 0.10-0.41). The use of metformin reduced cesarean section rates, resulted in a small number of patients to be treated, but it did not reduce LGA NB. Administering a lower dosage of metformin from the early stages to the end of treatment may yield significant results with fewer side effects. Arch Endocrinol Metab. 2020;64(3):290-7.Keywords
This publication has 28 references indexed in Scilit:
- Pre-Pregnancy Body Mass Index in Relation to Infant Birth Weight and Offspring Overweight/Obesity: A Systematic Review and Meta-AnalysisPLOS ONE, 2013
- Comment on: Rowan et al. Metformin in Gestational Diabetes: The Offspring Follow-Up (MiG TOFU): Body Composition at 2 Years of Age. Diabetes Care 2011;34:2279–2284Diabetes Care, 2012
- Metformin in Gestational Diabetes: The Offspring Follow-Up (MiG TOFU)Diabetes Care, 2011
- Metformin versus Insulin for the Treatment of Gestational DiabetesNew England Journal of Medicine, 2008
- Metformin Inhibits Hepatic Gluconeogenesis Through AMP-Activated Protein Kinase–Dependent Regulation of the Orphan Nuclear Receptor SHPDiabetes, 2008
- Metformin has no major effects on glucose homeostasis in pregnant women with PCOS: results of a randomized double‐blind studyScandinavian Journal of Clinical and Laboratory Investigation, 2008
- Gestational weight gain and macrosomia in a cohort of mothers and their childrenJornal de Pediatria, 2005
- Maternal birth weight in relation to plasma lipid concentrations in early pregnancyAmerican Journal of Obstetrics and Gynecology, 2004
- Assessment of weight gain during pregnancy in general prenatal care services in BrazilCadernos de Saude Publica, 2001
- A practical classification of newborn infants by weight and gestational ageThe Journal of Pediatrics, 1967